Abstract

Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is low, and the choices between intensive or low-intensity chemotherapy is often not clear. Geriatric and multidisciplinary interventions targeted to optimize functional status and improve management of comorbidities may enhance chemotherapy tolerance. Comprehensive geriatric assessment, and other integrated risk assessment models have been developed to predict the risk of chemotherapy-related toxicities and survival, and may guide therapy assignment. Development of low intensity but effective therapy is a major need. Deeper understanding of the molecular biology of AML has allowed several novel therapies to enter clinical trials in recent years. Continuation of successful collaboration between several stakeholders will be necessary to build upon the clinical and research improvements made thus far.

Original languageEnglish (US)
Pages (from-to)29-41
Number of pages13
JournalLeukemia and Lymphoma
Volume59
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Acute Myeloid Leukemia
Patient Care
Drug Therapy
Geriatrics
Comorbidity
Geriatric Assessment
Therapeutics
Survival
Cell Transplantation
Molecular Biology
Leukemia
Clinical Trials
Mortality
Research

Keywords

  • Acute myelogenous leukemia
  • geriatric
  • novel therapies
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{5d8a537babd24f2096d63b31c492e728,
title = "Initial therapy for acute myeloid leukemia in older patients: principles of care",
abstract = "Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is low, and the choices between intensive or low-intensity chemotherapy is often not clear. Geriatric and multidisciplinary interventions targeted to optimize functional status and improve management of comorbidities may enhance chemotherapy tolerance. Comprehensive geriatric assessment, and other integrated risk assessment models have been developed to predict the risk of chemotherapy-related toxicities and survival, and may guide therapy assignment. Development of low intensity but effective therapy is a major need. Deeper understanding of the molecular biology of AML has allowed several novel therapies to enter clinical trials in recent years. Continuation of successful collaboration between several stakeholders will be necessary to build upon the clinical and research improvements made thus far.",
keywords = "Acute myelogenous leukemia, geriatric, novel therapies, treatment",
author = "Bhatt, {Vijaya R} and Krishna Gundabolu and Koll, {Thuy T} and Maness-Harris, {Lori J}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/10428194.2017.1323275",
language = "English (US)",
volume = "59",
pages = "29--41",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Initial therapy for acute myeloid leukemia in older patients

T2 - principles of care

AU - Bhatt, Vijaya R

AU - Gundabolu, Krishna

AU - Koll, Thuy T

AU - Maness-Harris, Lori J

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is low, and the choices between intensive or low-intensity chemotherapy is often not clear. Geriatric and multidisciplinary interventions targeted to optimize functional status and improve management of comorbidities may enhance chemotherapy tolerance. Comprehensive geriatric assessment, and other integrated risk assessment models have been developed to predict the risk of chemotherapy-related toxicities and survival, and may guide therapy assignment. Development of low intensity but effective therapy is a major need. Deeper understanding of the molecular biology of AML has allowed several novel therapies to enter clinical trials in recent years. Continuation of successful collaboration between several stakeholders will be necessary to build upon the clinical and research improvements made thus far.

AB - Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is low, and the choices between intensive or low-intensity chemotherapy is often not clear. Geriatric and multidisciplinary interventions targeted to optimize functional status and improve management of comorbidities may enhance chemotherapy tolerance. Comprehensive geriatric assessment, and other integrated risk assessment models have been developed to predict the risk of chemotherapy-related toxicities and survival, and may guide therapy assignment. Development of low intensity but effective therapy is a major need. Deeper understanding of the molecular biology of AML has allowed several novel therapies to enter clinical trials in recent years. Continuation of successful collaboration between several stakeholders will be necessary to build upon the clinical and research improvements made thus far.

KW - Acute myelogenous leukemia

KW - geriatric

KW - novel therapies

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85020197967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020197967&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1323275

DO - 10.1080/10428194.2017.1323275

M3 - Review article

C2 - 28573900

AN - SCOPUS:85020197967

VL - 59

SP - 29

EP - 41

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -